Therapeutic | Denintuzumab |
Target | CD19 |
Heavy Chain | QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPGKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSS |
Light Chain | EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb ADC |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2014 |
INN Year Recommended | 2015 |
Companies Involved | Seattle Genetics |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Diffuse large B cell lymphoma, Follicular lymphoma, Non-Hodgkin's lymphoma, Precursor B-cell lymphoblastic leukaemia-lymphoma |
Notes |